Clinical Trials Logo

Clinical Trial Summary

The goal of this interventional clinical investigation using Genefill Contour® CE marked device outside of its indication is to compare with other hyaluronic acid device already marketed for labia majora augmentation in women with labia majora hypotrophy/atrophy. The primary objective is the evaluation of the safety of Genefill Contour®. The secondary objectives is effectivenes of the investigational device (improvement of patient´s symptoms, patient´s satisfaction, sexual function & pain during injection). Participants will come to a total of 8 visits (including 2 phone calls) over a period of 12 months. Participants would be enrolled in Genefill Contour® or comparator group. An ancillary study would be conducted in a cohort of participants evaluating the increase in volume and distance between labia after HA injection


Clinical Trial Description

Prospective, Multicentric, Single Blind, Randomized study on the evaluation of the safety and efficacy of Genefill Contour versus comparator in labia majora augmentation. This study analyze the safety and efficacy of the investigational device versus comparator. Participants would be randomized 1:1 between 2 arms (Genefill Contour vs comparator). The study duration is 12 months and will consist in 8 visits (Screening visit, 5 on site visit and 2 phone calls). At week 4, an optional touch-up may be conducted. 110 participants are expected to be included in the trial. The primary objective is the evaluation of the safety of Genefill Contour®. The secondary objectives is effectivenes of the investigational device (improvement of patient´s symptoms, patient´s satisfaction, sexual function & pain during injection). An ancillary study would be conducted in a cohort of participants evaluating the increase in volume and distance between labia after HA injection at W4 and W12. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06333782
Study type Interventional
Source Bioscience Cosmetics SL
Contact Dalia Quwaider, PhD, MBA
Phone 0034616711638
Email Dalia.quwaider@biosciencegmbh.com
Status Not yet recruiting
Phase N/A
Start date March 31, 2024
Completion date July 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT04705883 - Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors Phase 4
Completed NCT02937805 - Effects of a Moisturizing Cream on Vaginal and Vulvar Mucous Membranes N/A
Terminated NCT01753102 - Efficacy and Safety Of Spil's Estradiol Vaginal Tablet Phase 3
Completed NCT05378269 - Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA Phase 1/Phase 2
Completed NCT04147689 - Evaluation of the Efficacy and Safety of Hyaluronic Acid Injection in Labia Majora for Volume Restoration N/A
Recruiting NCT05890092 - Vulvar Disease in Nigeria Observational Study
Completed NCT02966925 - Autologous Platelet Concentrate Combined to Hyaluronic Acid Obtained With Cellular Matrix® BCT-HA Kit and Vulvovaginal Dryness N/A
Not yet recruiting NCT00453089 - VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women Phase 1/Phase 2
Recruiting NCT04042766 - Laser Vaginal Treatment for GSM N/A